Company: TELO
Filing Date: 2025-02-04
Form Type: 10-K
Source: 0001493152-25-004872
Chunk: 91

Company: Telomir Pharmaceuticals, Inc.
Filing Date: 2025-02-04
Form: 10-K
Item: Item 9B
Chunk 91
---
 Starwood Trust entered into a stock purchase agreement with the Company to purchase 142,857 shares
of unregistered common stock at $7 a share for a total of $1.0 million in proceeds to the Company.

71

Review
and Approval of Related Party Transactions

Our
board of directors adopted a written policy regarding the review and approval of related party transactions. Our audit committee charter
provides that the audit committee shall review and approve or disapprove any related party transactions, which are transactions between
us and related persons in which the aggregate amount involved exceeds or may be expected to exceed $120,000 and in which a related person
has or will have a direct or indirect material interest. Our policy regarding transactions between us and related persons will provide
that a related person is defined as a director, executive officer, nominee for director or greater than 5% beneficial owner of our common
stock, in each case since the beginning of the most recently completed year, and any of their immediate family members.

Certain
of the foregoing disclosures are summaries of certain provisions of our related party agreements and are qualified in their entirety
by reference to all of the provisions of such agreements. Because these descriptions are only summaries of the applicable agreements,
they do not necessarily contain all of the information that you may find useful. Copies of certain of the agreements have been filed
as exhibits to the registration statement of which this Annual Report is a part and are available electronically on the website of the
SEC at www.sec.gov.

As
a matter of corporate governance policy, we have not and will not make loans to officers or loan guarantees available to “promoters”
as that term is commonly understood by the SEC and state securities authorities.

All
future transactions between us and our officers, directors or five percent stockholders, and respective affiliates will be on terms no
less favorable than could be obtained from unaffiliated third parties and will be approved by a majority of our independent directors
who do not have an interest in the transactions and who had access, at our expense, to our legal counsel or independent legal counsel.

Item
14. Principal Accountant Fees and Services.

Audit
Fees. The aggregate fees billed by Cherry Bekaert LLP for professional services rendered for the audit of our annual financial statements,
review of the financial information included in our Forms 10-Q (where applicable) for the respective periods and other required filings
with the SEC for the years ended December 31, 2024 and December 31, 2023 totaled $